| Allergic rhinitis (disorder)
Qnasl vs Rayos
Side-by-side clinical, coverage, and cost comparison for allergic rhinitis (disorder).Deep comparison between: Qnasl vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayos has a higher rate of injection site reactions vs Qnasl based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Qnasl, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qnasl
Rayos
At A Glance
Intranasal
Daily
Intranasal corticosteroid
Oral
Daily
Corticosteroid
Indications
- Allergic rhinitis (disorder)
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
Dosing
Allergic rhinitis (disorder) - Adults and Adolescents (>=12 years) 320 mcg per day as 2 actuations in each nostril once daily (maximum 4 actuations per day) via QNASL 80 mcg Nasal Aerosol.
Allergic rhinitis (disorder) - Children (4 to 11 years) 80 mcg per day as 1 actuation in each nostril once daily (maximum 2 actuations per day) via QNASL 40 mcg Nasal Aerosol.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
- History of hypersensitivity to beclomethasone dipropionate and/or any other QNASL Nasal Aerosol ingredients
- Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=1%), adults and adolescents (>=12 years) Nasal discomfort, epistaxis, headache
Most common (>=2%), pediatric (4 to 11 years) Headache, pyrexia, upper respiratory tract infection, nasopharyngitis
Serious Epistaxis, nasal ulcerations, Candida albicans infection, impaired wound healing, eye disorders, hypercorticism, adrenal suppression, growth reduction, immunosuppression
Postmarketing Sneezing, burning sensation, nasal septal perforation, blurred vision, glaucoma, cataracts, central serous chorioretinopathy, loss of taste and smell, anaphylaxis, angioedema, rash, urticaria, bronchospasm
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
Beclomethasone dipropionate is a prodrug corticosteroid converted to the active metabolite beclomethasone-17-monopropionate, which inhibits inflammatory cells (mast cells, eosinophils, basophils, lymphocytes, macrophages, neutrophils) and release of inflammatory mediators (histamine, eicosanoids, leukotrienes, cytokines) involved in allergic rhinitis.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qnasl
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (9/12) · Qty limit (9/12)
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Qnasl
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Qnasl
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (3/3)
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Qnasl.
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.